Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months
Latest Information Update: 20 Jan 2026
At a glance
- Drugs PCV 24 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Sponsors Shanghai Reinovax Biologics
Most Recent Events
- 20 Jan 2026 New trial record